Pidilizumab
id:
pidilizumab-265-9663361
title:
Pidilizumab
text:
Pidilizumab is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effect
brand slug:
wiki
category slug:
encyclopedia
description:
Monoclonal antibody
original url:
https://en.wikipedia.org/wiki/Pidilizumab
date created:
date modified:
2023-12-01T20:47:12Z
main entity:
{"identifier":"Q7191298","url":"https://www.wikidata.org/entity/Q7191298"}
image:
fields total:
13
integrity:
14